产后口服葡萄糖耐受性测试的适应情况 来自GestDiab注册表的数据
Heinke Adamczewski1, Dietmar Weber, Judith Klein
1Diabetes Practice Cologne-East, Germany; winDiab GmbH, Kaarst, Germany; Antonius Hospital Cologne, Germany.
Deutsches Arzteblatt international
|March 6, 2024
概括
妊娠糖尿病 (GDM) 后糖尿病产后查可以通过估计前测试概率来改进. 这使得风险适应的咨询和有针对性的干预措施,可能减少口服葡萄糖耐受性测试 (OGT) 的需要.
科学领域:
- 内分泌学和新陈代谢学
- 生殖医学 生殖医学
- 公共卫生 公共卫生
背景情况:
- 孕期糖尿病 (GDM) 每年影响德国超过5万名孕妇.
- 目前产后查依赖于口服葡萄糖耐受性测试 (OGT),其粘附率低 (40%) 和潜在的副作用.
- 预测前测试概率的估计可以优化高风险个体的OGT使用.
研究的目的:
- 为了确定产后糖尿病 (DM) 或GDM后糖尿病前期的前测试概率.
- 确定用于估计这些概率的临床预测因素.
- 探索适应风险的产后查方法.
主要方法:
- 从GestDiab注册表 (2015-2019) 中分析了5444个GDM病例.
- 使用临床变量,产后禁食血葡萄糖 (FPG) 和血红蛋白A1c (HbA1c) 的测试前概率的计算.
- 包括诸如胰岛素治疗,肥胖,早期GDM诊断,产妇年龄和OGT1小时葡萄糖水平等预测因素.
主要成果:
- 在0.77%的母亲中,产后DM通过OGT诊断,GDM没有通过FPG或HbA1c检测到.
- 产后DM的测试前概率估计在0.11%至4.17%之间.
- 产后糖尿病的前测试概率在6.4%至16.3%之间,基于FPG,HbA1c和临床因素.
结论:
- 在GDM后产后糖尿病风险可以使用临床参数和生物标志物 (FPG,HbA1c) 来估计.
- 这使得风险适应的咨询和个性化的长期糖尿病预防策略成为可能.
- 建议进行进一步的研究以验证这些发现.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Pathophysiology of Diabetes
928
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
928
Diabetes: Symptoms, Diagnosis, and Complications
534
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
534
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Hypoglycemia and Glucagon
260
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
260


